CorMedix (CRMD) Change in Account Payables (2010 - 2025)
CorMedix (CRMD) posted Change in Account Payables of -$7.3 million for Q4 2025, down 211.79% sequentially from $6.5 million in Q3 2025, and down 2033.02% YoY from $375851.0 in Q4 2024.
CorMedix (CRMD) Change in Account Payables (2010 - 2025) Analysis & Trends
CorMedix has reported Change in Account Payables for 14 years, with the latest figure at -$7.3 million in Q4 2025.
- Quarterly Change in Account Payables fell 2033.02% year-over-year to -$7.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $3.3 million (up 230.04% YoY) and the FY2025 annual result came in at $3.3 million, up 230.04% from the prior year.
- Change in Account Payables slipped to -$7.3 million in Q4 2025 per CRMD's latest filing, from $6.5 million in the prior quarter.
- Over five years, Change in Account Payables peaked at $6.5 million in Q3 2025 and troughed at -$7.3 million in Q4 2025.
- A 4-year average of $252402.5 and a median of $375851.0 in 2024 frame the typical range for Change in Account Payables.
- The widest YoY moves for Change in Account Payables: up 648.76% in 2025, down 2033.02% in 2025.
- Over 4 years, Change in Account Payables stood at $434753.0 in 2022, then soared by 335.55% to $1.9 million in 2023, then plunged by 80.15% to $375851.0 in 2024, then slumped by 2033.02% to -$7.3 million in 2025.
- According to Business Quant data, Change in Account Payables over the past three periods registered -$7.3 million, $6.5 million, and $3.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -8.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 37.53 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | CorMedix | 645.20 Mn | 388.51 Mn | 77.13 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -7.27 Mn |
| Dec 31, 2025 | -7.27 Mn |
| Sep 30, 2025 | 6.50 Mn |
| Sep 30, 2025 | 6.50 Mn |
| Jun 30, 2025 | 3.88 Mn |
| Jun 30, 2025 | 3.88 Mn |
| Mar 31, 2025 | 212,950.00 |
| Mar 31, 2025 | 212,950.00 |
| Dec 31, 2024 | 375,851.00 |
| Dec 31, 2024 | 375,851.00 |
| Sep 30, 2024 | -2.00 Mn |
| Sep 30, 2024 | -2.00 Mn |
| Jun 30, 2024 | 518,482.00 |
| Jun 30, 2024 | 518,482.00 |
| Mar 31, 2024 | -1.45 Mn |
| Mar 31, 2024 | -1.45 Mn |
| Dec 31, 2023 | 1.89 Mn |
| Dec 31, 2023 | 1.89 Mn |
| Sep 30, 2023 | -514,450.00 |
| Sep 30, 2023 | -514,450.00 |